Soleno Therapeutics recently withdrew its European marketing application for VIOKAT XR while simultaneously agreeing to a cash acquisition by Neurocrine Biosciences, marking a pivotal shift in its operational outlook. The company’s business model centers on its approved rare disease therapy VYKAT XR targeting hyperphagia in Prader-Willi syndrome, supported by orphan drug status. Market exclusivity and leadership expertise underpin competitive advantages in a niche biopharma segment, though the near-term outlook faces execution risk tied to deal closure and regulatory repositioning. Investor focus now turns to the completion of the acquisition, integration prospects, and any residual regulatory milestones.